journal article·2024-02Open access

Long‐Acting Ocular Injectables: Are We Looking In The Right Direction?

Mickael Dang, Molly S. Shoichet

Advanced Science· Volume 11· Issue 8

Abstract

Abstract The complex anatomy and physiological barriers of the eye make delivering ocular therapeutics challenging. Generally, effective drug delivery to the eye is hindered by rapid clearance and limited drug bioavailability. Biomaterial‐based approaches have emerged to enhance drug delivery to ocular tissues and overcome existing limitations. In this review, some of the most promising long‐acting injectables (LAIs) in ocular drug delivery are explored, focusing on novel design strategies to improve therapeutic outcomes. LAIs are designed to enable sustained therapeutic effects, thereby extending local drug residence time and facilitating controlled and targeted drug delivery. Moreover, LAIs can be engineered to enhance drug targeting and penetration across ocular physiological barriers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced Drug Delivery Systems · Corneal Surgery and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering and Applied Chemistry University of Toronto 200 College Street Toronto ON M5S 3E5 Canada

Donnelly Centre for Cellular and Biomolecular Research University of Toronto 160 College Street Toronto ON M5S 3E1 Canada

Institute of Biomedical Engineering 164 College Street Toronto ON M5S 3G9 Canada

Funding

Krembil Foundation

References (100+)

Show source-provided references
1. 10.1038/s41578-021-00405-w10.1038/s41578-021-00405-w ↗
2. 10.1002/adhm.20190070210.1002/adhm.201900702 ↗
3. 10.1016/j.actbio.2020.04.05510.1016/j.actbio.2020.04.055 ↗
4. 10.1016/j.preteyeres.2016.12.00110.1016/j.preteyeres.2016.12.001 ↗
5. 10.1016/j.ijpharm.2021.12136110.1016/j.ijpharm.2021.121361 ↗
6. 10.1016/j.addr.2023.11486210.1016/j.addr.2023.114862 ↗
7. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
8. 10.1186/s12951-022-01751-910.1186/s12951-022-01751-9 ↗
9. 10.1002/mabi.20120021610.1002/mabi.201200216 ↗
10. 10.1007/s40266-020-00769-810.1007/s40266-020-00769-8 ↗
11. 10.1038/s41573-023-00670-010.1038/s41573-023-00670-0 ↗
12. 10.1038/s41433-020-0809-010.1038/s41433-020-0809-0 ↗
13. 10.1016/j.addr.2018.01.00810.1016/j.addr.2018.01.008 ↗
14. 10.1016/j.jconrel.2022.08.04010.1016/j.jconrel.2022.08.040 ↗
15. 10.1016/j.jconrel.2019.01.00710.1016/j.jconrel.2019.01.007 ↗
16. 10.3390/pharmaceutics1203026910.3390/pharmaceutics12030269 ↗
17. 10.1111/ceo.1202610.1111/ceo.12026 ↗
18. 10.3390/jcm1005098110.3390/jcm10050981 ↗
19. 10.1089/jop.2022.014410.1089/jop.2022.0144 ↗
20. 10.1111/vop.1284310.1111/vop.12843 ↗
21. 10.1038/s41598-019-56847-410.1038/s41598-019-56847-4 ↗
22. 10.2147/OPTH.S23306110.2147/OPTH.S233061 ↗
23. 10.2147/OPTH.S20797810.2147/OPTH.S207978 ↗
24. 10.1167/iovs.06-095410.1167/iovs.06-0954 ↗
25. 10.1517/17425247.1.1.9910.1517/17425247.1.1.99 ↗
26. 10.3390/bioengineering901004110.3390/bioengineering9010041 ↗
27. 10.1038/s41433-021-01412-510.1038/s41433-021-01412-5 ↗
28. 10.3109/08820538.2014.95919110.3109/08820538.2014.959191 ↗
29. 10.1016/j.preteyeres.2020.10090110.1016/j.preteyeres.2020.100901 ↗
30. 10.3390/pharmaceutics1301010810.3390/pharmaceutics13010108 ↗
31. WHO Glob. Data Vis. Impair. 20102010 p.17.
32. 10.1001/jamaophthalmol.2022.249510.1001/jamaophthalmol.2022.2495 ↗
33. 10.3390/ijms2003063610.3390/ijms20030636 ↗
34. 10.1016/j.drudis.2019.02.00110.1016/j.drudis.2019.02.001 ↗
35. 10.2165/00002018-200225010-0000410.2165/00002018-200225010-00004 ↗
36. 10.1016/j.preteyeres.2016.09.00310.1016/j.preteyeres.2016.09.003 ↗
37. 10.1111/cts.1259710.1111/cts.12597 ↗
38. 10.1016/j.preteyeres.2014.04.00210.1016/j.preteyeres.2014.04.002 ↗
39. 10.4155/tde.14.7510.4155/tde.14.75 ↗
40. 10.3390/polym1011122110.3390/polym10111221 ↗
41. 10.1167/iovs.08-298010.1167/iovs.08-2980 ↗
42. 10.3390/pharmaceutics1107032110.3390/pharmaceutics11070321 ↗
43. 10.2165/00003495-199958020-0001510.2165/00003495-199958020-00015 ↗
44. 10.1167/iovs.11-829310.1167/iovs.11-8293 ↗
45. 10.1007/978-1-4939-2272-7_310.1007/978-1-4939-2272-7_3 ↗
46. 10.3109/03639045.2012.73651510.3109/03639045.2012.736515 ↗
47. 10.1016/j.ejps.2018.07.03410.1016/j.ejps.2018.07.034 ↗
48. 10.1016/j.ajps.2020.08.00210.1016/j.ajps.2020.08.002 ↗
49. Kwatra D. · Methods Principles Med. Chem. · 2011 · 181
50. 10.1038/s44222-023-00082-010.1038/s44222-023-00082-0 ↗
51. 10.1080/14740338.2019.166278710.1080/14740338.2019.1662787 ↗
52. 10.4137/OED.S425310.4137/OED.S4253 ↗
53. 10.1038/nrd246810.1038/nrd2468 ↗
54. 10.3390/cells1207107110.3390/cells12071071 ↗
55. 10.1002/ctm2.82210.1002/ctm2.822 ↗
56. 10.3390/molecules2211192910.3390/molecules22111929 ↗
57. 10.1038/sj.mt.630032410.1038/sj.mt.6300324 ↗
58. 10.1021/acsnano.2c0582410.1021/acsnano.2c05824 ↗
59. 10.1002/psc.340810.1002/psc.3408 ↗
60. 10.1167/iovs.16-2007210.1167/iovs.16-20072 ↗
61. 10.1007/s12033-023-00679-110.1007/s12033-023-00679-1 ↗
62. Tang Z. · Adv. Sci. · 2022 · 9 · 1
63. 10.1016/j.jconrel.2022.05.05910.1016/j.jconrel.2022.05.059 ↗
64. 10.1016/j.addr.2017.12.00810.1016/j.addr.2017.12.008 ↗
65. 10.1007/s13346-021-00987-610.1007/s13346-021-00987-6 ↗
66. 10.1038/s41467-023-38056-w10.1038/s41467-023-38056-w ↗
67. 10.1021/acs.molpharmaceut.9b0015710.1021/acs.molpharmaceut.9b00157 ↗
68. 10.1089/jop.1992.8.3510.1089/jop.1992.8.35 ↗
69. 10.3390/ph1309024510.3390/ph13090245 ↗
70. 10.3390/ijms2203117010.3390/ijms22031170 ↗
71. 10.1016/S0002-9394(03)00675-510.1016/S0002-9394(03)00675-5 ↗
72. 10.1111/aos.1514810.1111/aos.15148 ↗
73. 10.1038/s41433‐023‐02553‐510.1038/s41433‐023‐02553‐5 ↗
74. 10.2147/OPTH.S23191310.2147/OPTH.S231913 ↗
75. 10.1038/s41433-019-0670-110.1038/s41433-019-0670-1 ↗
76. Thomas M. · Clin. Ophthalmol. · 2013 · 7 · 495
77. 10.1016/j.ajo.2019.01.00510.1016/j.ajo.2019.01.005 ↗
78. 10.1021/acs.accounts.1c0044010.1021/acs.accounts.1c00440 ↗
79. 10.2174/187152301666617050211581610.2174/1871523016666170502115816 ↗
80. 10.1093/protein/gzw05910.1093/protein/gzw059 ↗
81. 10.3390/v1410224210.3390/v14102242 ↗
82. 10.1007/s40259-020-00429-810.1007/s40259-020-00429-8 ↗
83. 10.1167/iovs.18-2530710.1167/iovs.18-25307 ↗
84. 10.1016/j.ajo.2012.09.03210.1016/j.ajo.2012.09.032 ↗
85. 10.1016/j.ajo.2014.05.03710.1016/j.ajo.2014.05.037 ↗
86. 10.32607/20758251-2019-11-4-42-5310.32607/20758251-2019-11-4-42-53 ↗
87. 10.3390/ijms2111376910.3390/ijms21113769 ↗
88. 10.1016/j.copbio.2011.06.00210.1016/j.copbio.2011.06.002 ↗
89. 10.1016/j.jconrel.2022.09.00410.1016/j.jconrel.2022.09.004 ↗
90. 10.1016/j.tibtech.2017.04.00710.1016/j.tibtech.2017.04.007 ↗
91. 10.1002/adma.20220261210.1002/adma.202202612 ↗
92. 10.1038/emm.2017.3510.1038/emm.2017.35 ↗
93. Luong Q. · Invest. Ophthalmol. Visual Sci. · 2022 · 63 · 3053
94. 10.1002/VIW.2020012610.1002/VIW.20200126 ↗
95. 10.3390/polym1308127210.3390/polym13081272 ↗
96. 10.1021/acs.chemrev.5b0034610.1021/acs.chemrev.5b00346 ↗
97. 10.3390/polym1212288110.3390/polym12122881 ↗
98. 10.1016/0142-9612(81)90059-410.1016/0142-9612(81)90059-4 ↗
99. 10.1016/j.bioactmat.2021.06.03510.1016/j.bioactmat.2021.06.035 ↗
100. 10.1016/j.jddst.2022.10343510.1016/j.jddst.2022.103435 ↗